GERN Insider Trading
GERON CORP | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at GERON CORP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 02:10 | 2026-02-18 | ROBERTSON MICHELLE | Officer - EVP, CHIEF FINANCIAL OFFICER | OPT+S | $1.94 | 9,855 | $19,119 | 17,645 | 0.0% |
| 2025-05-13 23:20 | 2025-05-09 | LAWLIS V BRYAN | Director | BUY | $1.18 | 13,300 | $15,667 | 13,300 | +100.0% |
| 2025-03-03 14:01 | 2025-02-27 | Samuels Scott Alan | Officer - EVP, Chief Legal Officer | BUY | $1.61 | 15,000 | $24,150 | 26,682 | +128.4% |
| 2025-03-03 14:01 | 2025-02-27 | SCARLETT JOHN A | Director, Officer - Chairman, President and CEO | BUY | $1.77 | 12,500 | $22,063 | 12,500 | +100.0% |
| 2025-03-03 14:01 | 2025-02-27 | Ziegler James | Officer - EVP, Chief Commercial Officer | BUY | $1.60 | 100,000 | $160,000 | 100,000 | +100.0% |
| 2024-07-10 23:05 | 2024-07-08 | GRETHLEIN ANDREW J | Officer - EVP, Chief Operating Officer | OPT+S | $4.56 | 674,348 | $3,073,004 | 0 | 0.0% |
| 2024-06-12 23:05 | 2024-06-10 | Feller Faye | Officer - EVP, Chief Medical Officer | OPT+S | $4.63 | 287,900 | $1,334,129 | 0 | 0.0% |
| 2024-06-12 23:05 | 2024-06-10 | Kapur Anil | Officer - EVP, Corp Strategy & CCO | OPT+S | $4.65 | 421,875 | $1,959,609 | 0 | 0.0% |
| 2024-06-05 23:05 | 2024-06-04 | SCARLETT JOHN A | Director, Officer - Chairman, President and CEO | OPT+S | $4.00 | 600,000 | $2,400,000 | 600,000 | 0.0% |
| 2024-05-17 23:05 | 2024-05-15 | LAWLIS V BRYAN | Director | OPT+S | $3.75 | 35,000 | $131,250 | 0 | 0.0% |
| 2023-08-25 03:52 | 2023-08-24 | O'Farrell Elizabeth G. | Director | BUY | $2.28 | 13,186 | $30,064 | 26,220 | +101.2% |
| 2023-05-12 04:01 | 2023-05-11 | LAWLIS V BRYAN | Director | OPT+S | $3.00 | 35,000 | $105,000 | 0 | 0.0% |
| 2023-05-02 04:20 | 2023-05-01 | Molineaux Susan | Director | OPT+S | $2.48 | 35,000 | $86,800 | 0 | 0.0% |
| 2023-02-11 05:49 | 2023-02-09 | GRETHLEIN ANDREW J | Officer - EVP, Chief Operating Officer | OPT+S | $3.03 | 384,719 | $1,165,699 | 0 | 0.0% |
| 2023-02-11 05:48 | 2023-02-08 | Bloom Olivia Kyusuk | Officer - EVP, Chief Financial Officer | OPT+S | $3.08 | 400,000 | $1,232,000 | 74,588 | 0.0% |
| 2023-02-11 05:47 | 2023-02-08 | SCARLETT JOHN A | Director, Officer - Chairman, President and CEO | OPT+S | $3.04 | 1,340,000 | $4,069,178 | 0 | 0.0% |
| 2020-08-25 03:57 | 2020-08-21 | O'Farrell Elizabeth G. | Director | BUY | $1.73 | 17,441 | $30,173 | 19,641 | +792.8% |
| 2020-01-14 05:10 | 2020-01-10 | O'Farrell Elizabeth G. | Director | BUY | $1.34 | 3,000 | $4,028 | 2,200 | +100.0% |
| 2019-04-11 02:45 | 2019-04-09 | BEHRS MELISSA KELLY | Officer - EVP, Chief Business Officer | SELL | $2.00 | 120,635 | $241,270 | 0 | -100.0% |
| 2018-09-14 04:28 | 2018-09-13 | Spiegel Robert J. | Director | OPT+S | $6.85 | 175,000 | $1,198,750 | 65,576 | 0.0% |
| 2018-08-25 04:32 | 2018-08-24 | ROSENFIELD STEPHEN | Officer - EVP, Genl Counsel & Secretary | OPT+S | $4.51 | 1,362,250 | $6,143,748 | 0 | 0.0% |
| 2015-06-02 04:12 | 2015-05-29 | Bloom Olivia Kyusuk | Officer - EVP, Chief Financial Officer | SELL | $3.84 | 2,380 | $9,139 | 74,588 | -3.1% |
| 2015-06-02 04:12 | 2015-05-29 | BEHRS MELISSA KELLY | Officer - EVP BD and Port&Alliance Mgmt | SELL | $3.84 | 2,380 | $9,139 | 120,635 | -1.9% |
| 2015-03-20 02:27 | 2015-03-18 | Hofstaetter Thomas | Director | OPT+S | $4.10 | 70,000 | $287,000 | 26,564 | 0.0% |
| 2013-04-02 04:46 | 2013-04-01 | SCARLETT JOHN A | Director, Officer - President and CEO | BUY | $1.03 | 50,000 | $51,500 | 125,000 | +66.7% |
| 2013-01-23 04:12 | 2013-01-17 | BEHRS MELISSA KELLY | Officer - SVP Alliance and Prog Mgmt | SELL | $1.65 | 28,292 | $46,569 | 0 | -100.0% |
| 2012-06-02 03:15 | 2012-05-30 | Kelsey Stephen Michael | Officer - EVP, R&D Head, CMO | SELL | $1.37 | 9,300 | $12,741 | 473,122 | -1.9% |
| 2012-06-02 03:15 | 2012-05-30 | EARP DAVID | Officer - SVP, Corp Transactions | SELL | $1.37 | 27,155 | $37,202 | 467,406 | -5.5% |
| 2012-06-02 03:14 | 2012-05-30 | Bloom Olivia Kyusuk | Officer - VP, Chief Acctg Officer | SELL | $1.37 | 11,029 | $15,110 | 147,782 | -6.9% |
| 2012-06-02 03:14 | 2012-05-30 | BEHRS MELISSA KELLY | Officer - SVP Strategic Portfolio Mgmt | SELL | $1.37 | 18,910 | $25,907 | 405,151 | -4.5% |
| 2012-02-09 04:29 | 2012-01-24 | SCARLETT JOHN A | Director, Officer - President and CEO | BUY | $1.72 | 75,000 | $129,000 | 75,000 | +100.0% |
| 2011-11-24 02:51 | 2011-11-22 | KILEY THOMAS | Director | BUY | $1.56 | 64,275 | $100,269 | 314,059 | +25.7% |
| 2011-10-07 03:35 | 2011-10-05 | KILEY THOMAS | Director | BUY | $2.03 | 50,000 | $101,500 | 96,653 | +107.2% |
| 2011-06-17 04:06 | 2011-06-14 | Spink Katharine E. | Officer - SVP Alliance Mgmt & Operations | SELL | $4.28 | 22,591 | $96,689 | 328,561 | -6.4% |
| 2011-06-17 04:05 | 2011-06-14 | LEBKOWSKI JANE | Officer - SVP, Chief Scientific Officer | SELL | $4.28 | 25,262 | $108,121 | 568,154 | -4.3% |
| 2011-06-17 04:04 | 2011-06-14 | Kelsey Stephen Michael | Officer - EVP, R&D Head, CMO | SELL | $4.28 | 4,858 | $20,792 | 476,773 | -1.0% |
| 2011-06-17 04:03 | 2011-06-14 | BEHRS MELISSA KELLY | Officer - SVP Strategic Portfolio Mgmt | SELL | $4.28 | 25,262 | $108,121 | 424,061 | -5.6% |
| 2011-06-17 04:02 | 2011-06-14 | GREENWOOD DAVID | Director, Officer - President, Interim CEO, CFO | SELL | $4.28 | 34,005 | $145,541 | 754,031 | -4.3% |
| 2011-06-17 03:58 | 2011-06-14 | EARP DAVID | Officer - Chief Legal Counsel | SELL | $4.28 | 25,262 | $108,121 | 494,561 | -4.9% |
| 2011-06-17 03:57 | 2011-06-14 | Bloom Olivia Kyusuk | Officer - VP, Chief Acctg Officer | SELL | $4.28 | 6,997 | $29,947 | 158,811 | -4.2% |
| 2011-05-25 04:41 | 2011-05-24 | Bloom Olivia Kyusuk | Officer - VP, Chief Acctg Officer | SELL | $4.47 | 1,200 | $5,364 | 165,808 | -0.7% |
| 2011-05-25 04:40 | 2011-05-24 | Spink Katharine E. | Officer - SVP Prgm Mgmt, Cell Therapies | SELL | $4.47 | 419 | $1,873 | 351,152 | -0.1% |
| 2011-05-25 04:40 | 2011-05-24 | BEHRS MELISSA KELLY | Officer - SVP Strategic Portfolio Mgmt | SELL | $4.47 | 2,975 | $13,298 | 449,323 | -0.7% |
| 2011-05-25 04:39 | 2011-05-24 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $4.47 | 2,975 | $13,298 | 519,823 | -0.6% |
| 2011-05-25 04:39 | 2011-05-24 | LEBKOWSKI JANE | Officer - SVP, Chief Scientific Officer | SELL | $4.47 | 2,975 | $13,298 | 593,416 | -0.5% |
| 2011-05-25 04:38 | 2011-05-24 | GREENWOOD DAVID | Director, Officer - President, Interim CEO, CFO | SELL | $4.47 | 4,462 | $19,945 | 788,036 | -0.6% |
| 2011-05-07 03:09 | 2011-05-05 | Kelsey Stephen Michael | Officer - EVP, CMO, Oncology | SELL | $4.83 | 14,163 | $68,407 | 364,131 | -3.7% |
| 2010-06-04 03:41 | 2010-06-02 | Spink Katharine E. | Officer - VP Operations, Regen Med Progs | SELL | $5.43 | 8,186 | $44,450 | 91,571 | -8.2% |
| 2010-06-04 03:40 | 2010-06-02 | LEBKOWSKI JANE | Officer - SVP, CSO Regen Med | SELL | $5.43 | 10,617 | $57,650 | 196,891 | -5.1% |
| 2010-06-04 03:37 | 2010-06-02 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $5.43 | 10,617 | $57,650 | 136,048 | -7.2% |
How to Interpret $GERN Trades
Not every insider transaction in GERON CORP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GERN shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for GERN
Insider activity data for GERON CORP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GERN, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.